This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Dynavax Technologies Corporation
Drug Names(s): HEPLISAV-B, V270, V-270, HBsAg-ISS
Description: Heplisav is based on Dynavax's proprietary immunostimulatory sequence (ISS) that specifically targets Toll-Like Receptor 9 (TLR-9) to stimulate an innate immune response. Heplisav combines ISS with HBV surface antigen (HBsAg) and is designed to significantly enhance the level, speed and longevity of protection.
Deal Structure: In June 2007, Coley and Dynavax entered into a license agreement relating to certain TLR Therapeutics patents from Coley. Under the terms of the agreement, Dynavax receives a non-exclusive license under Coley's immunostimulatory oligonucleotide patent estate for the commercialization of Heplisav, a hepatitis B prophylactic vaccine, currently in Phase III clinical trials. Coley will receive a $5.0 million up-front payment. Coley is also eligible to receive up to an additional $5.0 million upon regulatory approvals of Heplisav, as well as royalty payments for any future sales of Heplisav.
In November 2007, Dynavax and Merck announced a global license and development collaboration agreement to jointly develop Heplisav. Under the terms of the agreement, Merck receives worldwide exclusive rights to Heplisav, will fund future vaccine development, and be responsible for commercialization. Dynavax will receive an initial payment of $31.5 million, and will be eligible to receive up to...See full deal structure in Biomedtracker
Partners: Pfizer Inc.
Additional information available to subscribers only: